key: cord-0719649-b5bztqny
authors: Giannetti, Matthew P.; Weller, Emily; Alvarez-Twose, Iván; Torrado, Inés; Bonadonna, Patrizia; Zanotti, Roberta; Dwyer, Daniel F.; Foer, Dinah; Akin, Cem; Hartmann, Karin; Rama, Tiago Azenha; Sperr, Wolfgang R.; Valent, Peter; Teodosio, Cristina; Orfao, Alberto; Castells, Mariana
title: COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
date: 2021-02-23
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.02.023
sha: 351d8e05787854b3c32f437fa813d4a24c93e5b1
doc_id: 719649
cord_uid: b5bztqny

nan

Most patients had a mild course of COVID-19. Inpatient hospitalization was required in 12/28 91 (43%). One patient required intensive care unit admission for hypoxia; none required full 92 mechanical ventilation. One patient with ISM died from SARS-CoV-2-associated pneumonia. 93

His medical history was notable for multiple comorbidities that placed him at high risk for poor 94 outcomes including coronary artery disease with three stents, aortic valve replacement, atrial The hospitalization rate in our cohort is higher than current United States rates in the general 138 population; however, this may be due to international variation across sites, particularly in Spain 139 and Italy during the early months of the pandemic. It is also possible patients seek additional care 140 and/or are prophylactically hospitalized given the mast cell disorder comorbidity. The incidence 141 of asymptomatic MC activation patients infected with COVID-19 is unknown, and larger studies 142 are needed to validate our observations. Our study is also limited by patient recall of symptoms, 

Mast cells and influenza A virus: Association with allergic 164 responses and beyond

The dynamic changes in 166 cytokine responses in COVID-19: a snapshot of the current state of knowledge

Clinical Characteristics of 138 Hospitalized 169 Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Risk and 172 Management of Patients with Mastocytosis and MCAS

Pandemic: Expert Opinions *

Review Article Mastocytosis : 2016 updated WHO classi fi cation 176 and novel emerging treatment concepts

Activation and evasion of type I interferon 178 responses by SARS-CoV-2

Gene expression profile of highly purified bone marrow mast cells in systemic 181 mastocytosis

High expression of ACE2 receptor of 2019-183 nCoV on the epithelial cells of oral mucosa

SARS-CoV-2 186 pneumonia in hospitalized asthmatic patients did not induce severe exacerbation

Figure 1: Gene expression of ACE2, TLR3, and IL1RL1 on highly purified bone marrow mast cells from 199 normal/reactive (n=7) and systemic mastocytosis patients (n=26) from a